FDA Can Play a Critical Role in Holding Big Pharma Accountable and Promoting Competition, Transparency and Value
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement today on the U.S. Senate confirmation of Dr. Robert M. Califf to serve as commissioner of the U.S. Food and Drug Administration (FDA).
“CSRxP congratulates Dr. Califf for his confirmation and encourages the FDA to act swiftly to encourage greater competition, transparency and value in the prescription drug marketplace,” said CSRxP executive director Lauren Aronson. “The FDA can play a critical role in incentivizing the development of drugs that represent a meaningful improvement over existing medications, improving transparency in the prescription drug marketplace, and discouraging drug companies from engaging in behaviors that slow price competition.”
“Under Califf, the FDA should demand that all new medications provide strong, irrefutable evidence that they are safe and effective prior to reaching the market,” Aronson continued. “Such information is critical for patients who are already struggling to afford their medications and will also help discourage Big Pharma from pursuing profits over providing meaningful benefits for patients.”
Read CSRxP’s statement ahead of the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) vote to consider Dr. Califf’s nomination HERE.
Read CSRxP’s statement on the recent FDA approval of the first interchangeable biologic for Humira HERE.
Read CSRxP’s statement on the recent FDA approval of the first interchangeable biologic for an insulin product HERE.
Learn more about solutions to hold Big Pharma accountable and lower prescription drug prices HERE.